Nov 26, 2024
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
Nov 13, 2024
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
Nov 08, 2024
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
Nov 08, 2024
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Oct 01, 2024
LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
Sep 24, 2024
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Sep 23, 2024
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
Sep 09, 2024
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA(TM) (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
Aug 30, 2024
AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
Aug 20, 2024
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS
Aug 06, 2024
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Aug 02, 2024
AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
Aug 01, 2024
AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS
Jun 05, 2024
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Jun 05, 2024
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
May 16, 2024
FDA APPROVES IMDELLTRA(TM) (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
May 15, 2024
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
May 09, 2024
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
May 02, 2024
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
May 01, 2024
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024